If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEagle Eye Regulatory News (EYE)

Share Price Information for Eagle Eye (EYE)

Share Price is delayed by 15 minutes
Get Live Data
475.00    0.00 (0.00%)
Bid:
470.00
Ask:
480.00
Spread: 10.00 (2.128%)
Market Cap: £143.57m
EYE Live PriceLast checked at - London Stock Exchange

Intraday Eagle Eye Share Chart

Issue of Equity

5 Feb 2018 15:53

RNS Number : 9661D
Eagle Eye Solutions Group PLC
05 February 2018
 

 

5 February 2018

Eagle Eye Solutions Group PLC

("Eagle Eye", "Group" or the "Company")

 

Issue of Equity

 

 

Eagle Eye, a leading SaaS technology company that allows businesses to create a real-time connection with their customers, announces that it has applied for the admission to trading on AIM of 27,800 new ordinary shares of 1p each in the Company ("Ordinary Shares") following the exercise of certain options over Ordinary Shares. Dealings are expected to commence on 9 February 2018.

 

Following the issue of the 27,800 new Ordinary Shares, the total number of Ordinary shares in issue as at the date of this notice is 25,444,127 with each share carrying the right to one vote. There are no shares held in Treasury. The total number of voting rights in the Company is, therefore, 25,444,127.

 

The above figure of 25,444,127 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

 

For further information, please contact:

Tim Mason, Chief Executive Officer

Lucy Sharman-Munday, Chief Financial Officer

 

Tel: 0844 824 3686

Investec (Nominated Advisor and Broker)

Corporate Finance: David Anderson / Sebastian Lawrence

Corporate Broking: Rob Baker

 

Tel: 020 7597 5970

Hudson Sandler

Nick Lyon / Hattie O'Reilly

 

Tel: 020 7796 4133

Information on Eagle Eye

www.eagleeye.com

 

 

About Eagle Eye

 

Eagle Eye (LSE: EYE) is a leading SaaS technology company that allows businesses to create a real-time connection with their customers. The Company's digital marketing platform, Eagle Eye AIR, enables the secure, real-time, multi-channel issuance, management and redemption of digital promotions and rewards, replacing previously used paper-based methods. Established in 2003, the Company is headquartered in the UK with an international hub in Toronto and is a London Stock Exchange AIM listed company.

 

Eagle Eye's platform creates a network effect between merchants, distributors and brands enabling stronger connections and value to all parties. With these capabilities, Eagle Eye enables brands and merchants to reduce cost, improve their customer offer and accelerate their innovation. The Company's current customer base comprises Canada's food and pharmacy leader Loblaw as well as leading names in UK grocery, retail and hospitality including John Lewis, Asda, J Sainsbury, Greggs, JD Sports, Ladbrokes, Marks & Spencer, Mitchells & Butlers, Pizza Express, Tesco and Thomas Pink. The Board of Eagle Eye includes the CEO Tim Mason, previously Deputy CEO of Tesco plc and Sir Terry Leahy, Non-Executive Director, who was Chief Executive of Tesco plc until 2011.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEEELFBVLFEBBF
Date   Source Headline
17th Jun 20261:12 pmRNSIssue of Equity
28th May 20267:00 amRNSSale of shares from treasury
21st May 20262:47 pmRNSPDMR shareholding & issue of equity - replacement
21st May 20261:35 pmRNSPDMR shareholding and issue of equity
21st May 20267:00 amRNSCapital Markets Day
27th Apr 20267:00 amRNSNotice of Capital Markets Day
24th Apr 202612:30 pmRNSPDMR Shareholding
23rd Apr 20268:11 amRNSPDMR shareholding and issue of equity
31st Mar 20262:02 pmRNSPCA Shareholding
20th Mar 202610:36 amRNSDirector/PDMR Shareholding
17th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20267:00 amRNSHalf Year Results
17th Mar 20267:00 amRNSHalf Year Results
6th Mar 20267:00 amRNSTransaction in Own Shares & Programme Completion
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20265:18 pmRNSNotification of major holdings
2nd Mar 20262:43 pmRNSHolding(s) in Company
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20263:32 pmRNSDirector/PDMR Shareholding
12th Feb 202610:59 amRNSDirector/PDMR Shareholding
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSExtension of Share Buyback Long Stop Expiry Date
29th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
23rd Jan 20263:48 pmRNSDirector Declaration Update
20th Jan 20267:00 amRNSH1 FY26 Trading Update and Notice of Results
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSMajor US multi-year contract win
12th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.